Equities
  • Price (EUR)2.46
  • Today's Change0.02 / 0.82%
  • Shares traded0.00
  • 1 Year change+65.10%
  • Beta0.9280
Data delayed at least 15 minutes, as of Feb 16 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Zylox-Tonbridge Medical Technology Co Ltd is a China-based company primarily engaged in the provision of solutions to patients and physicians with the product portfolio covering neurovascular interventional devices and peripheral vascular interventional devices. The neurovascular interventional devices primarily include SilverSnake Intracranial Support Catheter, Phoenix Neurovascular Embolization Coil, Tonbridge Kylin Flow Diverter, Thrombite Clot Retriever Device and Beidou SS Neurovascular Guidewire. The peripheral vascular interventional devices primarily include UltraFree Drug Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter, ZYLOX Octoplus Retrievable Inferior Vena Cava Filter, Snare Retrieval Kit for Inferior Vena Cava Filter and ZYLOX Swan Endovenous Radiofrequency Ablation Catheter. The Company primarily operates its businesses in the domestic market and overseas markets, including Germany, France, Italy, and Turkiye.

  • Revenue in HKD (TTM)1.02bn
  • Net income in HKD172.82m
  • Incorporated2012
  • Employees875.00
  • Location
    Zylox-Tonbridge Medical Technology Co Ltd270 Shuyun RoadCangqian Street, Yuhang DistrictHANGZHOU ChinaCHN
  • Phone+86 57 188610082
  • Fax+86 57 188610608
  • Websitehttps://www.zyloxtb.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.